Elzonris(tagraxofusp)
Elzonris (tagraxofusp) is a protein pharmaceutical. Tagraxofusp was first approved as Elzonris on 2018-12-21. It is used to treat malignant histiocytic disorders in the USA. It has been approved in Europe to treat lymphoma.
Download report
Favorite
Drugs Approved for Childhood Cancers
Commercial
Trade Name
FDA
EMA
Elzonris
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Tagraxofusp
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Elzonris | tagraxofusp-erzs | Stemline Therapeutics | N-761116 RX | 2018-12-21 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| elzonris | Biologic Licensing Application | 2020-06-09 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| malignant histiocytic disorders | — | D015620 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
tagraxofusp, Elzonris, Stemline Therapeutics, Inc. | |||
| 2025-12-21 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9269 | Injection, tagraxofusp-erzs, 10 micrograms |
Clinical
Clinical Trials
16 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | C92.0 | 6 | 4 | — | — | — | 8 | |
| Myelomonocytic leukemia chronic | D015477 | C93.1 | 2 | 2 | — | — | — | 3 | |
| Myelodysplastic syndromes | D009190 | D46 | 2 | 1 | — | — | — | 2 | |
| Primary myelofibrosis | D055728 | D47.4 | 1 | 1 | — | — | — | 2 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 2 | 1 | — | — | — | 2 | |
| Multiple myeloma | D009101 | C90.0 | 1 | 1 | — | — | — | 1 | |
| Leukemia | D007938 | C95 | 1 | 1 | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TAGRAXOFUSP |
| INN | tagraxofusp |
| Description | Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
|
| Classification | Protein |
| Drug class | fusion proteins |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 2055491-00-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297573 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB14731 |
| UNII ID | 8ZHS5657EH (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 264 documents
View more details
Safety
Black-box Warning
Black-box warning for: Elzonris
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
113 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more